StockData
BRKRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BRKRP

BRUKER CORP

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$55.37+0.57 (+1.04%)

Close on Oct 19, 2026

Market cap
$8.43B
P/E (TTM)
–
Dividend yield
–

About Bruker

Laboratory Analytical Instruments, SIC 3826

Bruker develops, manufactures, and distributes high-performance scientific instruments alongside analytical and diagnostic solutions. Its technology platforms span magnetic resonance, mass spectrometry, chromatography, X-ray systems, microscopy, metrology, and molecular spectroscopy. The company organizes its business into four reportable segments: BSI BioSpin, BSI CALID, BSI NANO, and BEST. These offerings serve customers across life science and materials research, biopharmaceuticals, clinical microbiology, molecular diagnostics, nanotechnology, and industrial applied markets, including academic institutions, government bodies, healthcare providers, and commercial enterprises.

The company maintains major manufacturing and technical facilities across North America and Europe, complemented by sales offices globally. Bruker is headquartered in Billerica, Massachusetts.

Summary of the business section of Bruker's latest annual report, written by StockData.

Company profile

Company

Legal name
BRUKER CORP
Headquarters
Billerica, MA
Address
40 Manning Rd 01821
Phone
(978) 663-3660
Employees
11,085, Dec 31, 2025
Industry
Laboratory Analytical Instruments
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, Boston, Massachusetts

Stock & identifiers

Ticker
BRKR
Other tickers
BRKRP
Exchange
Nasdaq
IPO date
Aug 4, 2000
Shares outstanding
155M, Aug 3, 2026
Public float
$4.25B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1109354
CUSIP
116794108
ISIN
US1167941087
LEI
LEBZ6VLQ6I8XB1NHVY15
EIN
04-3110160

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Frank H. LaukienPRESIDENT & CEO, Director40,106,023
Mark MunchEXEC VP&PRES BRUKER NANO INC.134,806
Juergen SregaPRESIDENT CALID174,625
Burkhard PrausePRES. & CEO, BRUKER BEST28,461
Gerald N. HermanEXECUTIVE VICE PRESIDENT, CFO111,354
Wolfgang PuschPresident BMID Group9,801
Thomas BuresChief Accounting Officer7,233
Falko BussePRESIDENT, BIOSPIN GROUP48,171
Thierry BernardDirector2,886
Laura FrancisDirector9,018
Jack PhillipsDirector4,520
William A. LintonDirector63,243
John A. OrnellDirector39,732
Richard A. PackerDirector93,694
Bob RosenthalDirector38,781
Bonnie H. AndersonDirector17,847
Hermann Fritz RequardtDirector30,965
Cynthia M. FriendDirector22,536
Adelene Q. PerkinsDirector29,144

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Frank HLaukien Ph D
$4.71M$3.50M$1.76M$88$68
FY2024
Frank HLaukien Ph D
$5.53M$3.20M$2.08M$110$70
FY2023
Frank HLaukien Ph D
$5.86M$6.27M$2.01M$137$75
FY2022
Frank HLaukien Ph D
$5.06M$1.86M$1.71M$127$84
FY2021
Frank HLaukien Ph D
$5.59M$14.30M$1.97M$155$126
FY2020
Frank HLaukien Ph D
$4.08M$5.09M$1.46M$107$135

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Employees

Headcount reported in annual reports

“As of December 31, 2025, Bruker had approximately 11,085 employees worldwide.”

Corporate history

Events identified from SEC filings

DateEventDetails
Sep 8, 2025ListingRegistration of securities on an exchange (Form 8-A)
Aug 31, 2023Tender offerThird-party tender offer for the company's shares
Mar 5, 2020Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 3, 2020Late filingNotification of late filing
Mar 2, 2018Late filingNotification of late filing
Jun 3, 2016Auditor changeChange in certifying accountant (8-K Item 4.01)
Oct 7, 2010Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 4, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 2, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 26, 2010Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 11, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Feb 27, 2008Name changeName changed from BRUKER BIOSCIENCES CORP to BRUKER CORP
Feb 27, 2008Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jan 17, 2008Merger voteDefinitive merger proxy statement
Sep 14, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 7, 2006Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
May 25, 2006Merger voteDefinitive merger proxy statement
Mar 16, 2005Late filingNotification of late filing
Jul 2, 2003Name changeName changed from BRUKER DALTONICS INC to BRUKER BIOSCIENCES CORP
May 1, 2003MergerRegistration of securities for a merger or exchange offer (S-4)
Aug 4, 2000IPOInitial public offering priced (424B4 prospectus)